Cytopia has discovered a new class of orally bioavailable drugs that target and disrupt tumor vasculature.  Compounds of this chemical series are highly potent anticancer agents which are not susceptible to multi-drug resistance.
Read more
Cytopia, through its access to crystal structures of members of the JAK family of kinases and chemistry capabilities, has been successful in developing a portfolio of small molecule inhibitors of JAK3 that are both potent and specific.
Read more
Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease (MPD), cancer and pulmonary hypertension (PAH). The lead compound, CYT387, is expected to enter Ph I clinical trials in 2009.
Read more
10 July 2008
Cytopia strengthens scientific team with US based drug development specialist
18 June 2008
Cytopia to present data on FMS Program with Anticancer potential
16 May 2008
Release of Cytopia Abstract for CYT997 Oral Presentation at ASCO
8 May 2008
Novel Anti-Cancer Drug Development Collaboration
Share Registry
Link Market Services Ltd provide the share registry services to all Cytopia shareholders
Intellectual Property / Patents
Cytopia has a strong and growing intellectual property platform
Annual Reports
Archive of Cytopia's annual reports

To subscribe or unsubscribe to Cytopia email Announcements, please email cytopia@cytopia.com.au with the word 'subscribe' or 'unsubscribe' in the subject line.

Copyright © 2008 by Cytopia Ltd. All rights reserved. | Site use and privacy policy